View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
January 30, 2020updated 11 Jul 2022 9:54am

Superior efficacy of Brilinta in patients with stroke will boost the drug’s sales

By GlobalData Healthcare

AstraZeneca’s Brilinta (ticagrelor) met its primary endpoint in the Phase III THALES trial, boosting the blockbuster drug’s prospects in prevention of acute ischemic stroke (AIS) and transient ischemic attack (TIA).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

GlobalData believes that Brilinta’s use in these patients will significantly increase even before the approval in these indications, as the drug is currently used off-label in AIS and TIA patients, albeit very rarely. Nevertheless, the drug will face fierce competition with much cheaper clopidogrel (Plavix generics) and therefore AstraZeneca may focus on a very specific patient population (carriers of the CYP2C19 loss-of-function allele) to effectively capture a portion of the stroke market and significantly boost drug sales.

In combination with aspirin, Brilinta significantly decreased the risk of stroke or death over aspirin alone in patients who had suffered AIS or TIA and began treatment within 24 hours for 30 days. Provided the approval is obtained for the use of aspirin / Brilinta dual antiplatelet therapy (DAPT) in AIS and TIA, physicians would use the twice-daily Brilinta as a short-term 30-day treatment, as tested in the THALES trial. Previously, GlobalData’s primary research showed a very low level of off-label use of Brilinta globally, while in some countries, like the UK and Japan, no off-label use of this drug was detected.

Combining antiplatelet drugs to maximise efficacy is a common strategy in stroke prevention and the combination of aspirin and clopidogrel is the most commonly prescribed DAPT. Clinical trials have been investigating antiplatelet combinations that could be superior to aspirin monotherapy. In the POINT trial, clopidogrel combined with aspirin demonstrated reduced risk of major ischemic events occurring in patients with minor AIS or high-risk TIA. However, the trial also reported a higher risk of haemorrhage at 90 days in patients receiving the combination.

Some studies have shown that patients with minor AIS or TIA who are treated with Brilinta plus aspirin have a lower proportion of high platelet reactivity than those who are treated with clopidogrel plus aspirin, particularly for those who are carriers of the CYP2C19 loss-of-function allele.

GlobalData believes that Brilinta will likely be used as an add-on to aspirin in AIS and TIA patients carrying the CYP2C19 loss-of-function gene, as clopidogrel has decreased antiplatelet efficacy in patients who are poor metabolisers of CYP2C19. By targeting a niche population with specific unmet needs, the drug could steal some patient share from the much cheaper clopidogrel generics.

Brilinta is approved in all major markets for the treatment of acute coronary syndrome and for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack. Penetrating even a small portion of the stroke market would significantly boost the drug’s sales, as clopidogrel sales in 2019 (Plavix and clopidogrel generics), for stroke patients alone, were estimated to be close to $1bn, according to a GlobalData report.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology